Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
National Univ. Hospital Council to Disclose Funding with Companies’ Names Not Affiliated with JPMA
The National University Hospital Council of Japan will partially revise its guidelines for the disclosure of funding provided by drug makers and other companies. It plans to expand the disclosure range of names of companies that provided donations and compensation…
To read the full story
Related Article
- National University Hospital Council’s Guidelines Not to Require Disclosure of Individuals’ Names
October 7, 2014
- National University Hospital Council Announces Guidelines on Disclosure of Funding
June 23, 2014
- National University Hospitals to Disclose Funding from Autumn, but with Company Names Withheld
March 11, 2014
ORGANIZATION
- Pharma Labor Group Logs Wage Hikes of around 4% at July-End
August 24, 2026
- Biotech Group Calls for Post-IPO Startups to Get AMED Support
August 19, 2026
- EFPIA Executive Hails Japan’s Honebuto as “Blueprint” for Europe
August 17, 2026
- New Chuikyo Pharmacist Rep Urges 2027 Revision to Stay within 4-Minister Deal
August 3, 2026
- Ectopic Fat Research Group Launches to Push Cross-Disciplinary Studies
July 31, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…